Life Sciences Securities Litigation and Enforcement

Life Sciences Securities Litigation and Enforcement

Life Sciences

Key Contacts


  • Award Text

    Litigation-Securities Law Firm of the Year

    U.S. News - Best Lawyers®


  • Award Text

     Nationwide Ranking for Securities: Litigation

    Chambers USA


  • Award Text

     Life Cycle Firm of the Year

    LMG Life Sciences


  • U.S. News and World Report and Best Lawyers® named WilmerHale the 2023 Law Firm of the Year in Litigation – Securities. According to the directory, the recognition “reflects the highest level of respect a firm can earn among other leading lawyers and clients from the same communities and practice areas.”
  • Chambers USA consistently recognizes WilmerHale's distinguished Securities Litigation practice nationally and across several states, highlighting our strengths acting for clients in the technology and life sciences sectors. The legal directory guide notes that client sources praise our team for our “experience and skill at managing and responding to the very complex scientific issues that arise in the context of this type of litigation.”
  • LMG Life Sciences consistently recognizes WilmerHale as one of the nation’s leading law firms for life sciences clients, recommending our team for Non-IP Litigation, including securities litigation.
  • The Legal 500 United States consistently recognizes the firm in the area of securities litigation—defense. The guide notes that our attorneys are recognized for their “excellent record of trial victories and dismissals for life sciences companies,” with clients remarking that the firm has “very deep expertise in securities law matters” and “provides excellent advice and guidance.”


Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.